Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Donepezil Hydrochloride

FDA-approved product (tablet, oral), marketed as Adlarity, Aricept, Aricept Odt and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Donepezil Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Donepezil Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Donepezil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition

    NCT01504503 · start 2009-10

    Registered record
    Registry ID
    NCT01504503
    Conditions
    Healthy
    Interventions
    Donepezil Hydrochloride; Aricept
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-10
    Completion
    2009-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDonepezil Hydrochloride; Aricept
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition

    NCT01504516 · start 2009-10

    Registered record
    Registry ID
    NCT01504516
    Conditions
    Healthy
    Interventions
    Donepezil Hydrochloride; Aricept
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-10
    Completion
    2009-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDonepezil Hydrochloride; Aricept
    PhasePhase 1
    Registry statusCompleted

  • Progression Delaying Effect of Escitalopram in Alzheimer's Disease

    NCT00702780 · start 2008-11

    Registered record
    Registry ID
    NCT00702780
    Conditions
    Alzheimer's Disease
    Interventions
    escitalopram; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-09
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    Interventionescitalopram; placebo
    PhaseNot applicable
    Registry statusCompleted

  • Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

    NCT00766363 · start 2008-10

    Registered record
    Registry ID
    NCT00766363
    Conditions
    Alzheimer's Disease; Central Nervous System Diseases
    Interventions
    EVP-6124 (0.1 mg/day); EVP-6124 (0.3 mg/day); EVP-6124 (1.0 mg/day); Comparator: Placebo; Donepezil; Rivastigmine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Central Nervous System Diseases
    InterventionEVP-6124 (0.1 mg/day); EVP-6124 (0.3 mg/day); EVP-6124 (1.0 mg/day); Comparator: Placebo +2 more
    PhasePhase 1
    Registry statusCompleted

  • Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI

    NCT01379001 · start 2008-07

    Registered record
    Registry ID
    NCT01379001
    Conditions
    Cholinergic Function
    Interventions
    Scopolamine; Placebo; Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-07
    Completion
    2013-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholinergic Function
    InterventionScopolamine; Placebo; Donepezil
    PhaseNot applicable
    Registry statusCompleted

  • An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

    NCT01245530 · start 2008-06

    Registered record
    Registry ID
    NCT01245530
    Conditions
    Alzheimer Type Dementia
    Interventions
    Aricept; INM-176
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-06
    Completion
    2011-03
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Type Dementia
    InterventionAricept; INM-176
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial of Donepezil Between the Naive Group and the Switching Group

    NCT01023425 · start 2008-02

    Registered record
    Registry ID
    NCT01023425
    Conditions
    Alzheimer's Disease; Dementia
    Interventions
    donepezil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-04
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Dementia
    Interventiondonepezil
    PhaseNot applicable
    Registry statusCompleted

  • Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease

    NCT00602680 · start 2008-01

    Registered record
    Registry ID
    NCT00602680
    Conditions
    Alzheimer's Disease
    Interventions
    SSR180711C; donepezil; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-01
    Completion
    2008-07
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionSSR180711C; donepezil; placebo
    PhasePhase 2
    Registry statusTerminated

  • Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

    NCT00711204 · start 2008-01

    Registered record
    Registry ID
    NCT00711204
    Conditions
    Severe Alzheimer's Disease
    Interventions
    Donepezil Hydrochloride (Aricept)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-01
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Alzheimer's Disease
    InterventionDonepezil Hydrochloride (Aricept)
    PhasePhase 4
    Registry statusWithdrawn

  • Donepezil 10 mg Tablets Under Fasting Conditions

    NCT01439230 · start 2007-06

    Registered record
    Registry ID
    NCT01439230
    Conditions
    Healthy
    Interventions
    Donepezil; Aricept®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDonepezil; Aricept®
    PhasePhase 1
    Registry statusCompleted

  • Donepezil Double Blind Trial for ECT Memory Disfunction

    NCT00465283 · start 2007-05

    Registered record
    Registry ID
    NCT00465283
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    Interventions
    Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-05
    Completion
    2010-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    InterventionDonepezil
    PhasePhase 4
    Registry statusUnknown

  • Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

    NCT00428090 · start 2007-02-27

    Registered record
    Registry ID
    NCT00428090
    Conditions
    Alzheimer's Disease
    Interventions
    Rosiglitazone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-02-27
    Completion
    2008-09-05
    Enrolment
    862

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionRosiglitazone
    PhasePhase 3
    Registry statusCompleted

  • Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

    NCT00452868 · start 2006-06

    Registered record
    Registry ID
    NCT00452868
    Conditions
    Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity
    Interventions
    Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2006-06
    Completion
    2010-02
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors; Cognitive/Functional Effects; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity +2 more
    InterventionDonepezil
    PhaseEarly phase 1
    Registry statusCompleted

  • 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

    NCT01260922 · start 2006-04

    Registered record
    Registry ID
    NCT01260922
    Conditions
    Healthy
    Interventions
    Donepezil Hydrochloride; Aricept®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-04
    Completion
    2006-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDonepezil Hydrochloride; Aricept®
    PhasePhase 1
    Registry statusCompleted

  • An Open-Label Trial of Donepezil in Fragile X Syndrome

    NCT00220584 · start 2005-07

    Registered record
    Registry ID
    NCT00220584
    Conditions
    Fragile X Syndrome
    Interventions
    donepezil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-07
    Completion
    2009-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFragile X Syndrome
    Interventiondonepezil
    PhasePhase 1
    Registry statusCompleted